CLVTMEDIUM SIGNALFINANCIAL10-K

CLVT substantially reduced its net losses while decreasing share count and maintaining stable cash position.

The company's meaningfully improved bottom line suggests either enhanced operational efficiency or one-time charges from the prior period that did not recur. The reduction in outstanding shares from 691.6 million to 640.7 million indicates active capital management through buybacks or other corporate actions, which should benefit remaining shareholders.

Comparing 2026-02-24 vs 2025-02-19View on EDGAR →
FINANCIAL ANALYSIS

CLVT's financial position shows notable improvement with net losses substantially reduced from $636.7 million to $201.1 million, indicating either operational progress or non-recurring prior-year charges. Cash and equivalents grew modestly to $329.2 million, providing adequate liquidity while the company reduced its share count by approximately 51 million shares. The overall picture suggests a company making meaningful progress on profitability while actively managing its capital structure.

FINANCIAL STATEMENT CHANGES
Net Income
P&L
+68.4%
-$636.7M-$201.1M

Net income grew 68.4% — bottom-line growth signals improving overall business health.

Cash & Equivalents
Balance Sheet
+11.5%
$295.2M$329.2M

Cash grew 11.5% — improving liquidity position supports investment and shareholder returns.

LANGUAGE CHANGES
NEW — 2026-02-24
PRIOR — 2025-02-19
ADDED
The number of ordinary shares of the Company outstanding as of January 31, 2026 , was 640,698,582 .
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.
Certain Relationships and Related Transactions, and Director Independence.
Unless otherwise indicated, throughout this annual report, dollar and euro amounts are presented in millions, except for per share amounts.
Our aim is to fuel the world s greatest breakthroughs by harnessing the power of human ingenuity.
From research and learning to commercialization, we offer intelligence solutions, workflow solutions, and tech-enabled services to customers in the Academia Government, Intellectual Property, and Life Sciences Healthcare end markets.
Continuously enriched, up-to-date knowledge assets, combining expert-curated data, structured taxonomies, and analytical models that transform complex information into actionable insights powered by a unique combination of AI-enabled software and human expertise.
We are home to industry specialists, consultants, and data scientists with deep subject- matter expertise and global experience.
Our highly curated, proprietary suite of branded information and insights solutions developed through our sourcing, aggregation, verification, translation, classification, and standardization processes combined with AI and other advanced technologies, positions us to deliver amplified intelligence in the age of AI.
REMOVED
The number of ordinary shares of the Company outstanding as of January 31, 2025, was 691,638,374 .
Market for Registrant s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 23 Item 6.
Management s Discussion and Analysis of Financial Condition and Results of Operations 25 Item 7A.
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 71 Item 9A.
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 73 Item 13.
Unless otherwise indicated, dollar amounts throughout this annual report are presented in millions of dollars, except for per share amounts.
Our name, Clarivate, is derived from three powerful words: clarity, activate, and innovate.
We connect people and organizations to the intelligence they can trust to transform their perspective, their work, and our world.
Whether it s providing insights to advance an industry or accelerating the delivery of a critical drug, our vision at Clarivate is to fuel the world s greatest breakthroughs by harnessing the power of human ingenuity.
We offer enriched data, insights analytics, workflow solutions, and expert services to our customers in the Academia Government, Intellectual Property, and Life Sciences Healthcare end markets.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →